Cargando…
Role of zoledronic acid in the prevention and treatment of osteoporosis
Taken once a year, intravenous zoledronic acid (Zol) (Reclast(®) or Aclasta(®)) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In gluco...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095556/ https://www.ncbi.nlm.nih.gov/pubmed/21594000 http://dx.doi.org/10.2147/CIA.S7282 |